KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

– Patient perspectives reveal the challenges of injecting on-demand therapies and the consequences of delayed or withheld treatment -

– Physicians characterize breakthrough HAE attacks occurring in patients receiving non-androgen long-term prophylaxis -

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the European Academy of Allergy and Clinical Immunology Congress 2024 that took place in Valencia, Spain.

The following presentations occurred at EAACI 2024:

• Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated? Cristine Radojicic, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina, USA. (Flash Talks Session)
  • For 50% of US survey respondents with HAE, their untreated attack progressed in severity while 25% of attacks migrated to other anatomic locations including the throat
  • Common reasons for not treating were desire to save injectable on-demand treatment for a severe attack, presumption the attack would stay mild, wanting to avoid needle pain or injection burning, stinging, or pain, and not having on-demand treatment with them
• Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers Rashmi Jain, Consultant in Clinical Immunology, Oxford University Hospital Trust, Oxford, UK. (Poster presentation)
  • 63% of UK survey participants reported their perception of time to treatment for HAE attacks as “early” despite only 14% treating in less than one hour
  • Common barriers to early on-demand treatment included the belief that the attack was going to remain mild and wanting to save injectable on-demand treatment for a severe attack
• Anxiety Associated with On-Demand Treatment for Hereditary Angioedema Attacks Patrick Yong, Frimley Health NHS Foundation Trust, Frimley, UK. (Poster presentation)
  • Almost half of UK survey participants reported moderate to extreme anxiety when anticipating use of injectable on-demand therapy to treat an attack
  • Top reasons for feeling anxious were desire not to ‘waste’ on-demand treatment, uncertainty about how long the treatment would take to begin working, and finding a vein for IV infusion
• Patient-Reported Benefits of Early On-demand Treatment of HAE Attacks Hilary Longhurst, Auckland City Hospital, Te Toka Tumai, and University of Auckland, Auckland, New Zealand. (Poster presentation)
  • Results from this analysis highlight that survey respondents with HAE who treat their attacks early (